Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive following the news it's been granted patents for its CelGro® collagen rope in China and Hong Kong, bringing the number of countries it is patented in to five. The collagen rope product, part of the company’s CelGro® collagen scaffold platform technology, is designed to augment ligament repair surgeries such as anterior cruciate ligament (ACL) reconstruction.
Orthocell welcomes further Asian patent protection for CelGro collagen rope
Quick facts: Orthocell Ltd
Price: 0.51 AUD
Market Cap: $97.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE